Plasma cytokine levels and coagulation and complement activation during use of the extracorporeal liver assist device in acute liver failure

Artificial Organs

Volumn 22, Issue 10, 1998, Pages 854-858

  Hughes, Robin D ^a   Nicolaou, Nicholas ^a   Langley, Peter G ^a   Ellis, Antony J ^a   Wendon, Julia A ^a   Williams, Roger ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Artificial liver; Coagulation; Complement; Cytokines; Liver failure

Indexed keywords

ANTIBIOTICS; ARTIFICIAL ORGANS; BLOOD PRESSURE; FIBER OPTIC SENSORS; GLYCOPROTEINS; LEFT VENTRICULAR ASSIST DEVICES; PATIENT TREATMENT;

ACUTE LIVER FAILURE; ARTIFICIAL LIVER; COMPLEMENT; COMPLEMENT ACTIVATIONS; CYTOKINE PRODUCTION; CYTOKINES; HEMOPERFUSION; LIVER ASSIST DEVICE; LIVER FAILURE; MULTIPLE ORGAN FAILURE;

COAGULATION;

C REACTIVE PROTEIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ARTIFICIAL LIVER; BLOOD CLOTTING; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; DIALYSIS MEMBRANE; FEMALE; HUMAN; IMMUNOREGULATION; INTERFERON PRODUCTION; LIVER FAILURE; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031679801     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1998.06162.x     Document Type: Article

References (18)

1. Langley PG, Forbes A, Hughes RD, Williams R. Thrombin-antithrombin III complex in fulminant hepatic failure: Evidence for disseminated intravascular coagulation and relationship to outcome. Eur J Clin Invest 1989;20:627-31.
2. Wyke RJ, Rajkovic IA, Eddleston ALWF, Williams R. Defective opsonization and complement deficiency in serum from patients with fulminant hepatic failure. Gut 1980;21: 643-6.
3. Muto Y, Noun-Aria KT, Meager A, Alexander GJ, Eddleston AL, Williams R. Enhanced TNF and IL-1 in fulminant hepatic failure. Lancet 1988;2:72-4.
4. De La Mata M, Meager A, Rolando N, Daniels H, Williams R. TNF-α production in fulminant hepatic failure: A relation to aetiology and superimposed microbial infection. Clin Exp Immunol 1990;82:479-84.
5. Izumi S, Hughes RD, Langley PG, Pernambuco JRB, Williams R. Extent of the acute phase response in fulminant hepatic failure. Gut 1994;35:982-6.
6. Keane HM, Sheron N, Goka J, Hughes RD, Williams R. Plasma inhibitory activity against tumor-necrosis factor in fulminant hepatic failure. Clin Sci 1996;60:77-80.
7. Hughes RD, Williams R. Use of bioartificial and artificial liver support devices. Semin Liver Dis 1996;435-44.
8. Nagaki M, Hughes RD, Keane HM, Lau JYN, Williams R. In vitro plasma perfusion through adsorbents and plasma ultrafiltration to remove endotoxin and cytokines. Circ Shock 1992;38:182-8.
9. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, Gislason GT, Sussman NL, Williams R. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;42:1446-51.
10. Gislason GT, Lobdell DD, Kelly JH, Sussman NL. A treatment system for implementing an extracorporeal liver assist device. Artif Organs 1994;18:385-9.
11. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device. Artif Organs 1994; 18:390-6.
12. Highton J, Hessian P. A solid phase enzyme immunoassay for C-reactive protein: Clinical value and the effect of rheumatoid factor. J Immunol Methods 1984;68:186-92.
13. Memoli B, Libetta C, Rampino T, Dal Canton A, Conte G, Scala G, Ruocco MR, Andreucci VE. Hemodialysis related induction of interleukin-6 production by peripheral blood mononuclear cells. Kidney Int 1992;42:320-6.
14. Chollet-Martin S, Stamatakis G, Bailly S, Mery JP, Gougerot-Pocidalo MA. Induction of tumour necrosis factor-alpha during haemodialysis. Influence of the membrane type. Clin Exp Immunol 1991;83:329-32.
15. Canivet E, Lavaud S, Wong T, Guenounou M, Willemin JC, Potron G, Chanard J. Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor-alpha levels during hemodialysis. Am J Kidney Dis 1994;23:41-6.
16. Pertosa G, Tarantino EA, Gesualdo L, Montinaro V, Schena FP. C5h-9 generation and cytokine production in hemodialyzed patients. Kidney Int 1993;41(Suppl.):S221-5.
17. Gardinali M, Calcagno A, Conciato L, Agostoni A, Rosti A, Cori P, Vozzo N, Moroni A, Anelli A, Zoni U, Del Preto M. Complement activation in dialysis: Effects on cytokines, lymphocyte activation and beta-2 microglohulin. Int J Artif Organs 1994;17:337-44.
18. Tedesco F, Pausa M, Nardon E, Introna M, Mantovani A, Dobrina A. The cytolytically inactive terminal complement complex activates endothelial cells to express adhesion molecules and tissue factor procoagulant activity. J Exp Med 1997;9:1619-27.